Aspiriant LLC’s Schwab Fundamental Emerging Markets Large Company Index ETF FNDE Stock Holding History

Aspiriant LLC’s Portfolio FNDE Stock Details FNDE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.4M	Sell	539,037 -5,856	-1%	-$237K	0.53%	29
2026 Q1	$20.8M	Buy	544,893 +2,644	+0.5%	+$102K	0.59%	27
2025 Q4	$19.6M	Sell	542,249 -81,847	-13%	-$2.99M	0.56%	28
2025 Q3	$22.6M	Sell	624,096 -12,015	-2%	-$414K	0.69%	26
2025 Q2	$21M	Sell	636,111 -18,710	-3%	-$581K	0.67%	27
2025 Q1	$20.2M	Sell	654,821 -11,044	-2%	-$334K	0.7%	20
2024 Q4	$19.3M	Sell	665,865 -42,951	-6%	-$1.34M	0.7%	21
2024 Q3	$22.9M	Sell	708,816 -17,566	-2%	-$525K	0.87%	18
2024 Q2	$21.5M	Sell	726,382 -21,752	-3%	-$632K	0.88%	18
2024 Q1	$20.8M	Sell	748,134 -170,552	-19%	-$4.6M	0.86%	20
2023 Q4	$24.9M	Sell	918,686 -145,805	-14%	-$3.83M	1.12%	15
2023 Q3	$27.9M	Buy	1,064,491 +31,069	+3%	+$835K	1.43%	12
2023 Q2	$27.7M	Sell	1,033,422 -4,455	-0.4%	-$118K	1.4%	12
2023 Q1	$27M	Sell	1,037,877 -142,163	-12%	-$3.7M	1.42%	11
2022 Q4	$29.2M	Buy	1,180,040 +19,950	+2%	+$489K	1.49%	12
2022 Q3	$27.2M	Buy	1,160,090 +846,196	+270%	+$21.6M	1.33%	19
2022 Q2	$8.14M	Buy	313,894 +242,537	+340%	+$6.64M	0.39%	33
2022 Q1	$2.07M	Buy	71,357 +798	+1%	+$24.3K	0.11%	86
2021 Q4	$2.19M	Buy	70,559 +13,533	+24%	+$433K	0.12%	83
2021 Q3	$1.84M	Buy	57,026 +7,272	+15%	+$232K	0.11%	78
2021 Q2	$1.6M	Buy	49,754 +13,244	+36%	+$422K	0.09%	85
2021 Q1	$1.12M	Sell	36,510 -35,355	-49%	-$1.06M	0.07%	94
2020 Q4	$2.03M	Buy	71,865 +22,273	+45%	+$581K	0.14%	64
2020 Q3	$1.18M	Buy	49,592 +25,532	+106%	+$629K	0.09%	92
2020 Q2	$563K	Buy	24,060 +1,967	+9%	+$44.1K	0.05%	124
2020 Q1	$454K	Buy	+22,093	New	+$579K	0.04%	131
2018 Q4	–	Sell	-7,173	Closed	-$205K	–	234
2018 Q3	$205K	Buy	+7,173	New	+$202K	0.02%	225
2018 Q2	–	Sell	-7,173	Closed	-$224K	–	252
2018 Q1	$224K	Buy	+7,173	New	+$225K	0.02%	224

Other funds holding FNDE

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BWL

Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Foster & Motley Cincinnati, Ohio $2.17B AUM 27.73% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Aspiriant LLC's FNDE Position: Q2 2026 in Review

Aspiriant LLC reduced its Schwab Fundamental Emerging Markets Large Company Index ETF (FNDE) stake by 1.1% in Q2 2026, selling an estimated $237K and leaving 539,037 shares worth $21.4M. The position accounts for 0.53% of the portfolio, ranked #29.

Aspiriant LLC first reported a position in FNDE in Q1 2018 and has held it in 28 quarters since. The position peaked at $29.2M in Q4 2022. 494 funds tracked by Wall St. Rank hold FNDE as of Q2 2026.

Aspiriant LLC held 539,037 shares of Schwab Fundamental Emerging Markets Large Company Index ETF worth $21.4M as of Q2 2026.
Aspiriant LLC sold 5,856 Schwab Fundamental Emerging Markets Large Company Index ETF shares in Q2 2026, an estimated $237K.
Schwab Fundamental Emerging Markets Large Company Index ETF made up 0.53% of Aspiriant LLC's portfolio in Q2 2026, its #29 holding.
Aspiriant LLC first reported a position in Schwab Fundamental Emerging Markets Large Company Index ETF in Q1 2018 and has held it in 28 quarters since.
Aspiriant LLC's Schwab Fundamental Emerging Markets Large Company Index ETF position peaked at $29.2M in Q4 2022.
494 funds tracked by Wall St. Rank held Schwab Fundamental Emerging Markets Large Company Index ETF as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.